The process begins with the collection of T cells from the patient's blood. These cells are then genetically modified in the laboratory to produce CARs (chimeric antigen receptors) on their surface. After expansion, the modified T cells are infused back into the patient. The CAR enables the T cells to recognize and attach to a specific protein on the cancer cells, leading to their destruction.
